- Home
- INO
as 12-17-2024 4:00pm EST
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 110.7M | IPO Year: | 1998 |
| Target Price: | $16.33 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.91 - $14.75 | Next Earning Date: | 11-14-2024 |
| Revenue: | $203,413 | Revenue Growth: | -76.18% |
| Revenue Growth (this year): | -84.17% | Revenue Growth (next year): | 2290.97% |
Latest Inovio Pharmaceuticals Inc. News
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Top Midday Decliners
MT Newswires
5 days ago
Inovio Prices $30 Million Public Offering of Shares, Accompanying Warrants
PR Newswire
5 days ago
INOVIO Announces Pricing of $30 Million Public Offering
PR Newswire
5 days ago
INOVIO Announces Proposed Public Offering
PR Newswire
15 days ago
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
PR Newswire
18 days ago
INOVIO Reports Inducement Grant Under Inducement Plan
MT Newswires
a month ago
Oppenheimer Adjusts Inovio Pharmaceuticals Price Target to $15 From $33, Maintains Outperform Rating
Simply Wall St.
a month ago
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)
Compare INO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.